Who Owns Sarepta Therapeutics Inc
Every manager with more than $100m in listed equities files a 13F each quarter naming what they hold. These are the ones reporting a position in Sarepta Therapeutics Inc.
Who crossed 5% of SRPT →Positions as of 2026-09-30
Largest first. The move is against the previous quarter that manager filed, not the previous calendar quarter.
| Manager | Value |
|---|---|
| GAMMA Investing LLCCommon Stock2.2K shtrimmed | $39.9K |
| ATWOOD & PALMER INCCOM1.4K shheld | $25.5K |
| Farther Finance Advisors, LLCStock1.1K shtrimmed | $20.2K |
| CoreCap Advisors, LLCStock292 shadded | $5.3K |
| MassMutual Private Wealth & Trust, FSBCommon / Ordinary Stock129 shtrimmed | $2.4K |
| MJT & Associates Financial Advisory Group, Inc.Stock69 shheld | $1.3K |
| GILPIN WEALTH MANAGEMENT, LLCCOM9 shheld | $164 |
| Davis Capital ManagementStock6 shheld | $109 |
Source: quarterly 13F filings, via EDGAR. A 13F reports positions by CUSIP alone; each CUSIP here has been confirmed against OpenFIGI rather than matched by name, because a name match would attribute one company's shareholders to another. Positions are as of quarter end and can be months old by the time they are filed, and 13F covers long equity positions only — not shorts, and not most debt. The summed value is what these filers reported, not the company's institutional ownership.
More on SRPT
Follow Sarepta Therapeutics Inc (SRPT) by email
New trades in Sarepta Therapeutics Inc (SRPT) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.